The private placement attracted significant interest from institutional investors, including participation from members of RenovoRx's executive management team and board of directors. The purchase price for the shares sold to institutional investors was set at $0.938 per share, while insiders paid a slightly higher price of $1.0288 per share to comply with Nasdaq regulations. The financing is anticipated to enhance RenovoRx's operational capabilities, reduce cash burn, and move the company closer to achieving cash-flow breakeven operations.
In conjunction with the financing, RenovoRx has committed to filing a registration statement with the U.S. Securities and Exchange Commission (SEC) for the resale of the shares and warrants issued in the private placement. This step is crucial for ensuring liquidity for investors and facilitating future capital raises.
The company aims to leverage the proceeds from this financing to accelerate its commercialization strategy for RenovoCath, which is designed for targeted drug delivery in cancer treatment. The funds will also support the completion of the TIGeR-PaC trial, with full enrollment expected by mid-2026 and results anticipated in 2027. RenovoRx's innovative approach to oncology therapy positions it well for future growth, and this successful financing round is a significant step in that direction.
